Oramed Pharmaceuticals Inc. — Director's Dealing 2016

Dec 7, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2016-12-05

Reporting Person: RAKIN KEVIN (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-12-05	Common Stock	A	2300	$6.3761	Acquired	11761	Direct
2016-12-06	Common Stock	A	3300	$6.5948	Acquired	15061	Direct

Footnotes

F1: This transaction was executed in multiple trades at prices ranging from $6.36 to $6.39. The price reported above in Column 4 of Table I reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer complete information regarding the number of shares and prices at which each of the individual transactions was effected.

F2: This transaction was executed in multiple trades at prices ranging from $6.40 to $6.65. The price reported above in Column 4 of Table I reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer complete information regarding the number of shares and prices at which each of the individual transactions was effected.